论文部分内容阅读
目的:评价伊立替康单药与联合消癌平注射液治疗老年晚期胃癌的疗效及安全性。方法:回顾性收集2012-2014年我院收治的老年晚期胃癌患者60例,按治疗方案的不同分为联合组和单药组,各30例。单药组患者采用伊立替康(CPT-11)150 mg/m2加入250 ml 0.9%氯化钠注射液,ivgtt,联合组患者在单药组基础上加用消癌平注射液80 ml,qd。两组患者均14 d为1个周期,连续治疗4个周期。比较两组患者肿瘤标志物水平、疾病控制率、无进展生存期(PFS)及不良反应发生率。结果:治疗后,两组患者肿瘤标志物血清癌胚抗原、糖类抗原199、糖类抗原242水平显著低于治疗前,且联合组明显低于单药组,差异有统计学意义(P<0.05);联合组患者疾病控制率为70.00%,显著高于单药组的33.33%,联合组患者PFS为(11.23±2.17)个月,显著长于单药组的(9.36±0.84)个月,差异均有统计学意义(P<0.05);联合组患者白细胞减少、丙氨酸转氨酶升高、腹泻、口腔黏膜炎及手足综合征的不良反应发生率显著低于单药组,差异有统计学意义(P<0.05)。结论:消癌平注射液联合伊立替康治疗老年晚期胃癌效果明显,不良反应发生率低。
OBJECTIVE: To evaluate the efficacy and safety of irinotecan monotherapy combined with Xiaoqiaoping injection in the treatment of elderly patients with advanced gastric cancer. Methods: Sixty elderly patients with advanced gastric cancer who were admitted to our hospital from 2012 to 2014 were retrospectively collected. According to the different treatment regimens, they were divided into combined group and single drug group, with 30 cases in each group. Patients in the monotherapy group were given irinotecan (CPT-11) 150 mg / m2 by adding 250 ml of 0.9% sodium chloride injection, ivgtt. The combination group was treated with 80 mg of Xiaojianping injection plus qd . Two groups of patients were 14 days for a cycle, continuous treatment for 4 cycles. The levels of tumor markers, disease control rate, progression-free survival (PFS) and incidence of adverse reactions in both groups were compared. Results: After treatment, the levels of serum carcinoembryonic antigen, carbohydrate antigen 199 and carbohydrate antigen 242 in the two groups were significantly lower than those before treatment, and the combined group was significantly lower than the single drug group (P < 0.05). The combined control group had a disease control rate of 70.00%, significantly higher than that of the single drug group (33.33%). The PFS of the combined group was (11.23 ± 2.17) months, significantly longer than that of the single drug group (9.36 ± 0.84) (P <0.05). The incidences of leukopenia, elevated alanine aminotransferase, diarrhea, oral mucositis and hand-foot syndrome in the combined group were significantly lower than those in the single drug group Significance (P <0.05). Conclusion: Xiao-ping-ping injection combined with irinotecan in the treatment of advanced gastric cancer has obvious effect, the incidence of adverse reactions is low.